Reading CNTN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTN free→Reading CNTN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CNTN free→QuarterlyIQ Insights · CNTN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. 2026 Share Repurchase Program On June 11, 2026, the Board of Directors the Company approved a share repurchase program (the “ 2026 Share Repurchase Program ”) providing for the repurchase of up to $50 million of the Company’s outstanding shares of Common Stock. Under the 2026 Share Repurchase Program, the Company is authorized to repurchase shares of Common Stock through open market purchases, privately-negotiated transactions, or otherwise in accordance with applicable federal…
Regulation FD Disclosure. On June 16, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) issued a press release announcing the 2026 Share Repurchase Program (as defined below), a copy of which is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, will not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any filing under the S…
Material Definitive Agreement On March 3, 2026, Canton Strategic Holdings, Inc. (the “ Company ”), entered into an amended and restated sales agreement (the “ Sales Agreement ”) with Clear Street LLC (“ Clear Street ”) and Virtu Americas LLC (“ Virtu ”, and together with Clear Street, the “ Sales Agents ”), relating to the sale of shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”). The Sales Agreement amends and restates the ATM Sales Agreement, dated as…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 5, 2026, the Board of Directors (the “ Board ”) of Tharimmune, Inc. (the “ Company ”) appointed Angela Dominy Radkowski, age 37, as Chief Operating Officer of the Company, effective February 5, 2026 (the “ Effective Date ”). Prior to her appointment, Ms. Radkowski served as Operations Strategy Lead and Chief of Staff to the Chief Operat…
Entry into a Material Definitive Agreement. Underwriting Agreement On January 20, 2026, Tharimmune, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Clear Street LLC, as the sole underwriter (the “Underwriter”), relating to an underwritten registered offering to a single institutional investor (the “Offering”) of (i) 1,800,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $2.9200 (…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 9, 2026, Tharimmune, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires, among other things, that a majority of the Board of Directors of the Company (the “Board”) be comprised of independent directors. As previously disclosed, Nancy Davis and Sanam Parikh resign…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) appointed Jacob Asbury, age 52, as Chief Financial Officer of the Company, effective December 10, 2025 (the “Effective Date”). Mr. Asbury will replace Mr. Sireesh Appajosyula, who will step down from the role of Interim Chief Financial Officer and will co…
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On November 7, 2025, the Board of Directors of Tharimmune, Inc. (the “Company”) appointed Sireesh Appajosyula as interim Chief Financial Officer for a period not to extend beyond December 31, 2025. Mr. Appajosyula’s previously disclosed employment agreement with the Company remains in effect. - 2 - SIGNATURES Pursuant to the requirements of the Sec…
Other Events. On November 6, 2025, the Company issued a press release announcing the closing of its private placement offering. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this
Material Definitive Agreement On November 6, 2025, the Company entered into an ATM Sales Agreement (the “ Sales Agreement ”) with Clear Street LLC and President Street Global LLC, as sales agents (the “ Agents ”) to sell shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $64,910,161 (the “ ATM Shares ”) from time to time, through an “at the market offering” (the “ ATM Offering ”) as defined in Rule 415 under the Securities Act of 1933, as amen…
Other Events. As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 3, 2025, Tharimmune, Inc. (the “Company”) entered into securities purchase agreements (the “ Cash Securities Purchase Agreements ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of either…
Unregistered Sales of Equity Securities. The information under
Entry into a Material Definitive Agreement. Securities Purchase Agreements On November 3, 2025, Tharimmune, Inc. (the “ Company ”) entered into securities purchase agreements (the “ Cash Securities Purchase Agreements ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of either shares (the “ Cash Shares ”) of common stock of th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Special Meeting (as defined below) on October 9, 2025, the stockholders approved an amendment to the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder to 2,000,000 shares from 792,602 shares. The foregoing descriptions of the Plan Amendme…
Entry into a Material Definitive Agreement. On October 1, 2025, Tharimmune, Inc. entered into a warrant amendment with the holders of warrants to purchase an aggregate 3,408,110 shares of common stock to amend such warrants to make them immediately exercisable. - 2 - SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 Tharimmune,…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2025, the Compensation Committee (the “Committee”) of the Board of Directors of Tharimmune, Inc. (the “Company”) approved an increase of $100,000 in the base salary of each of Sireesh Appajosyula, the Company’s CEO, and Vincent LoPriore, the Executive Chairman of the Company, to $385,000. In addition, the Committee approved an incre…
Other Events. On April 1, 2025, Tharimmune, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that its stockholders equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2,500,000. On May 15, 20…
Entry into a Material Definitive Agreement. On August 26, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) in relation to a registered direct offering (the “Offering”) with certain purchasers, under the Shelf Registration Statement (as defined below), of $5.35 million of the Company’s securities (the “Securities”), consisting of 1,188,888 shares of Common Stock, par value $0.0001 per share (or common stock equivalents) at a price o…
Entry into a Material Definitive Agreement. On August 26, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) in relation to a registered direct offering (the “Offering”) with certain purchasers, under the Shelf Registration Statement (as defined below), of $5.35 million of the Company’s securities (the “Securities”), consisting of 1,188,888 shares of Common Stock, par value $0.0001 per share (or common stock equivalents) at a price o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2025, the board of directors (the “Board”) of Tharimmune, Inc. (the “Company”) appointed Nancy Davis as a member of the Board effective as of August 4, 2025. Ms. Davis will serve for a term expiring at the 2026 annual meeting of stockholders. Ms. Davis’ ongoing annual compensation will be consistent with that provided to the Company’s…
Entry into a Material Definitive Agreement On July 25, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited individual and institutional investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 641,190 shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 103,490 s…
Entry into a Material Definitive Agreement. On July 23, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) in relation to a registered direct public offering (the “Offering”) with certain purchasers, under the Shelf Registration Statement (as defined below), of $1.74 million of the Company’s securities (the “Securities”), consisting of (i) 414,331 shares of Common Stock, par value $0.0001 per share (the “Common Stock”) and 559,910 pr…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 22, 2025, Kelly Anderson resigned from the Board of Directors of Tharimmune, Inc. for personal reasons, effective immediately. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 24, 2025…
Entry into a Material Definitive Agreement On June 13, 2025, Tharimmune, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited individual and institutional investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 1,551,351 shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 137,838…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2025, Don Kim, Chief Financial Officer of Tharimmune, Inc. (the “Company”) resigned from his position as CFO for personal reasons, effective immediately. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly a…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.